Absence of acute cocaine interactions with the MAO-B inhibitor selegiline.
Selegiline, an irreversible monoamine oxidase-B (MAO-B) inhibitor, is under investigation as a treatment for cocaine relapse prevention. To evaluate its safety, human volunteers (n = 5) received intravenous cocaine (0, 20 and 40 mg, 1 h apart) following treatment with placebo or selegiline (10 mg, p.o.). Cocaine increased heart rate, blood pressure, pupil diameter and subjective indices of euphoria and craving. Selegiline produced no measureable effects, except for miosis, and did not alter the effects of cocaine. These data suggest that selegiline may be safely administered in combination with cocaine, and that selegiline is unlikely to increase reinforcing effects of cocaine.
Haberny
K A
KA
Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21224-6823, USA.
Walsh
S L
SL
Ginn
D H
DH
Wilkins
J N
JN
Garner
J E
JE
Setoda
D
D
Bigelow
G E
GE
D000284:Administration, Oral; D000328:Adult; D001143:Arousal / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D003042:Cocaine / Q000009:adverse effects*; D018592:Cross-Over Studies; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D004347:Drug Interactions; D005059:Euphoria / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008996:Monoamine Oxidase Inhibitors / Q000008:administration & dosage / Q000009:adverse effects*; D012025:Reflex, Pupillary / Q000187:drug effects; D012642:Selegiline / Q000008:administration & dosage / Q000009:adverse effects*; D013375:Substance Withdrawal Syndrome / Q000209:etiology; D019966:Substance-Related Disorders / Q000534:rehabilitation
D008996:Monoamine Oxidase Inhibitors; D012642:Selegiline; D003042:Cocaine